<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="220656">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211159</url>
  </required_header>
  <id_info>
    <org_study_id>OmegAD#1</org_study_id>
    <nct_id>NCT00211159</nct_id>
  </id_info>
  <brief_title>OmegAD (Omega-3 and Alzheimer's Disease)</brief_title>
  <official_title>Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <brief_summary>
    <textblock>
      Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be
      due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see
      if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment
      in AD patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition measured according to ADAS-cog, MMSE scales</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerability, blood pressure</measure>
  </secondary_outcome>
  <enrollment>204</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPAX 1050TG</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Alzheimer's disease with MMSE 15-30, living in own homes, treated with
        stable dose of acetylcholine esterase inhibitor for &gt;3 months and remaining on that
        treatment for the study period

        Exclusion Criteria: Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an
        alcohol abuser, suffering from serious concomitant disease or not having a caregiver
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tommy Cederholm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8.</citation>
    <PMID>17030655</PMID>
  </results_reference>
  <verification_date>April 2005</verification_date>
  <lastchanged_date>February 7, 2007</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Omega-3 fatty acid</keyword>
  <keyword>Dietary supplementation</keyword>
  <keyword>Cognition</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
